Apellis Pharmaceuticals Inc [APLS] stock is trading at $25.12, down -2.37%. An important factor to consider is whether the stock is rising or falling in short-term value. The APLS shares have gain 5.55% over the last week, with a monthly amount drifted -1.10%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on September 26, 2025, when Goldman downgraded its rating to a Sell but kept the price target unchanged to $18 for it. Previously, Raymond James downgraded its rating to Outperform on May 09, 2025, and kept the price target unchanged to $52. On May 09, 2025, downgrade downgraded it’s rating to Neutral but maintained its price target of $23 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $44 on April 29, 2025. Goldman downgraded its rating to a Neutral but $36 remained the price target by the analyst firm on December 17, 2024. Morgan Stanley started tracking with a Equal-Weight rating for this stock on November 21, 2024, and assigned it a price target of $31. In a note dated October 25, 2024, RBC Capital Mkts initiated an Sector Perform rating and provided a target price of $25 on this stock.
Apellis Pharmaceuticals Inc [APLS] stock has fluctuated between $16.10 and $35.72 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $25.12 at the most recent close of the market. An investor can expect a potential drop of -20.38% based on the average APLS price forecast.
Analyzing the APLS fundamentals
Apellis Pharmaceuticals Inc [NASDAQ:APLS] reported sales of 754.65M for the trailing twelve months, which represents a drop of -10.61%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.25%, Pretax Profit Margin comes in at -0.3%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.16 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Apellis Pharmaceuticals Inc’s Current Ratio is 3.77. On the other hand, the Quick Ratio is 3.16, and the Cash Ratio is 1.85. Considering the valuation of this stock, the price to sales ratio is 4.20, the price to book ratio is 20.28.
Transactions by insiders
Recent insider trading involved Dunlop A. Sinclair, Director, that happened on Sep 30 ’25 when 31092.0 shares were sold. Director, Dunlop A. Sinclair completed a deal on Sep 19 ’25 to sell 31092.0 shares. Meanwhile, Director Dunlop A. Sinclair bought 93276.0 shares on Sep 19 ’25.
